RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine

  • Anja Seckinger
  • Tomi Bähr-Ivacevic
  • Vladimir Benes
  • Dirk HoseEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1792)


RNA sequencing is a recently developed approach for transcriptome profiling with several advantages over gene expression profiling using DNA microarrays. Here we describe a RNA-sequencing protocol optimized for low-input analysis of total RNA from CD138+ purified plasma cells from myeloma patients which is applicable in clinical routine.

Key words

Multiple myeloma RNA-sequencing Low input Clinical application 



This work was in part supported by grants from the German Federal Ministry of Education (BMBF) within the framework of the e:Med research and funding concept “CLIOMMICS” (01ZX1309 and 01ZX1609) and the Deutsche Forschungsgemeinschaft (DFG SFB/TRR79; TP B1 and B12).


  1. 1.
    Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31(34):4325–4332CrossRefGoogle Scholar
  2. 2.
    Seckinger A, Hose D (2015) Dissecting the Clonal Architecture of Multiple Myeloma. Paper presented at the 20th Congress of the European Hematology Association, Vienna, AustriaGoogle Scholar
  3. 3.
    Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, Vos JD, Hundemer M, Condomines M, Bertsch U, Rossi J-F, Jauch A, Klein B, Möhler T (2009) Induction of angiogenesis by normal and malignant plasma cells. Blood 114(1):128–143CrossRefGoogle Scholar
  4. 4.
    Hose D, Reme T, Hielscher T, Moreaux J, Meissner T, Seckinger A, Benner A, Shaughnessy JD, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Mohler T, Rossi JF, Jauch A, Klein B, Goldschmidt H (2011) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96:87–95CrossRefGoogle Scholar
  5. 5.
    Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, Vos JD, Rossi J-F, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113(18):4331–4340CrossRefGoogle Scholar
  6. 6.
    Seckinger A, Meißner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Reme T, Rosen-Wolff A, Jauch A, Schnettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D (2012) Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 120(5):1087–1094. CrossRefPubMedGoogle Scholar
  7. 7.
    Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, Vos JD, Rossi JF, Möhler T, Klein B, Hose D (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28(44):3866–3879CrossRefGoogle Scholar
  8. 8.
    Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa A-M, Sotto J-J, Wetterwald M, Dumontet C, Fuzibet J-G, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau J-L, Facon T, Mathiot C (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe francophone du Myelome. Blood 109(8):3489–3495CrossRefGoogle Scholar
  9. 9.
    Meißner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D (2011) Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine. Clin Cancer Res 17(23):7240–7247CrossRefGoogle Scholar
  10. 10.
    Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6):2276–2284CrossRefGoogle Scholar
  11. 11.
    Reme T, Hose D, Theillet C, Klein B (2013) Modeling risk stratification in human cancer. Bioinformatics 29(9):1149–1157. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau J-L, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S, du Myélome IF (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe francophone du Myélome. J Clin Oncol 26(29):4798–4805CrossRefGoogle Scholar
  13. 13.
    Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1):296–303CrossRefGoogle Scholar
  14. 14.
    Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD (2006) The molecular classification of multiple myeloma. Blood 108(6):2020–2028CrossRefGoogle Scholar
  15. 15.
    Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD (2017) Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31(3):396–410CrossRefGoogle Scholar
  16. 16.
    Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS (2013) Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 3(8):862–869. CrossRefPubMedGoogle Scholar
  17. 17.
    Seckinger A, Meissner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B, Hose D (2015) miRNAs in multiple myeloma—a survival relevant complex regulator of gene expression. Oncotarget 6(36):39165–39183. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Anja Seckinger
    • 1
  • Tomi Bähr-Ivacevic
    • 1
  • Vladimir Benes
    • 2
  • Dirk Hose
    • 1
    Email author
  1. 1.Labor für Myelomforschung, Medizinische Klinik VUniversitätsklinikum HeidelbergHeidelbergGermany
  2. 2.Genomics Core Facility, European Molecular Biology LaboratoryHeidelbergGermany

Personalised recommendations